BeOne Medicines's total inventories for the quarter that ended in Mar. 2026 was MXN12,291 Mil. BeOne Medicines's average total inventories from the quarter that ended in Dec. 2025 to the quarter that ended in Mar. 2026 was MXN11,621 Mil.
In Ben Graham's calculation of Net-Net Working Capital, inventory is only considered worth half of its book value. BeOne Medicines's Net-Net Working Capital per share for the quarter that ended in Mar. 2026 was MXN331.39.
Days Inventory indicates the number of days of goods in sales that a company has in the inventory.
BeOne Medicines's Days Inventory for the
three
months ended in Mar. 2026 was 351.68.
Inventory Turnover measures how fast the company turns over its inventory within a year.
BeOne Medicines's Inventory Turnover for the quarter that ended in Mar. 2026 was 0.26.
Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
BeOne Medicines's Inventory-to-Revenue for the quarter that ended in Mar. 2026 was 0.43.
BeOne Medicines (MEX:BGNEN) Total Inventories Explanation
Inventory control is an important part of business operation. If a company does not have enough inventory, it may not be able to meet customers' required delivery time. If it has too much inventory, the cost of holding the inventory can be high.
1. In Ben Graham's calculation of Net-Net Working Capital (NNWC), inventory is only considered worth half of its book value.
BeOne Medicines's Net-Net Working Capital Per Share for the quarter that ended in Mar. 2026 is
4. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
BeOne Medicines's Inventory to Revenue for the quarter that ended in Mar. 2026 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
Manufacturers with durable competitive advantages have the advantage that the products they sell do not change, and therefore will never become obsolete. Buffett likes this advantage.
When identifying manufacturers with durable competitive advantage, look for inventory and net earnings that rise correspondingly. This indicates that the company is finding profitable ways to increase sales which called for an increase in inventory.
Manufacturers with inventories that spike up and down are indicative of competitive industries subject to boom and bust.
BeOne Medicines Total Inventories Related Terms
BeOne Medicines Total Inventories Historical Data
* Premium members only.
The historical data trend for BeOne Medicines's Total Inventories can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Total Inventories includes the raw materials, work-in-process goods and completely finished goods of a company. It is a portion of a company's current assets.
What does a Total Inventories of MXN12,291 Mil mean?
BeOne Medicines (MEX:BGNEN) has a Total Inventories of MXN12,291 Mil as of Mar. 2026. The total amount of inventory as recorded on a company's balance sheet. View historical data for BeOne Medicines and its competitors.
Is BeOne Medicines' Total Inventories too high?
BeOne Medicines' current Total Inventories is MXN12,291 Mil. Overall, BeOne Medicines has a GF Score™ of 81/100, reflecting its overall financial health beyond just this single metric.
How does BeOne Medicines' Total Inventories compare to RVMD and RPRX?
BeOne Medicines' Total Inventories of MXN12,291 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Inventories for a Biotechnology company?
A good Total Inventories depends on the Biotechnology industry context. However, Total Inventories should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Inventories mean?
A high Total Inventories can signal that a stock is expensive relative to its fundamentals. The total amount of inventory as recorded on a company's balance sheet. View historical data for BeOne Medicines and its competitors. BeOne Medicines's current Total Inventories is MXN12,291 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is BeOne Medicines stock overvalued right now?
BeOne Medicines (MEX:BGNEN) has a current Total Inventories of MXN12,291 Mil. The stock's GF Value™ is MXN3,774.03, compared to a current price of MXN2,858.16 — trading 24.3% below its estimated fair value. The current Total Inventories is MXN12,291 Mil. BeOne Medicines' overall GF Score™ is 81/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Inventories calculated?
Total Inventories is calculated from a company's financial statements. For BeOne Medicines (MEX:BGNEN), the current Total Inventories is MXN12,291 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is BeOne Medicines (MEX:BGNEN) Overvalued in 2026?
Based on GuruFocus' analysis, BeOne Medicines stock appears to be undervalued.
The current stock price of MXN2,858.16 is trading 24.3% below its estimated GF Value™ of MXN3,774.03.
Key valuation signals for MEX:BGNEN:
Total Inventories: MXN12,291 Mil
GF Value™: MXN3,774.03 vs. price of MXN2,858.16 (24.3% below fair value)
No single metric tells the full story. See the MEX:BGNEN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Formerly known as BeiGene and founded in 2010 in Beijing, BeOne is a commercial-stage biotech firm that produces oncology therapeutics. The company's main product is Brukinsa, which is a small-molecule drug that treats multiple forms of Non-Hodgkin lymphoma and leukemia. The company conducts drug discovery, runs global clinical trials, and manufactures drugs independently. As of 2025, Brukinsa made up for 74% of total revenue, while it has two other approved commercialized drugs in its portfolio, Beqalzi and Tevimbra. While Brukinsa has a global leadership, the other two drugs generate revenue mostly from China. Based on Brukinsa, BeOne competes with AbbVie and AstraZeneca mainly. The company also has more than 50 drugs in clinical trials in its active pipeline, focused on other cancers.
81GF Score
Get the complete analysis for MEX:BGNEN
Total Inventories is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MEX:BGNEN has been successfully added to your 
